
Bionano Genomics (BNGO) Stock Forecast & Price Target
Bionano Genomics (BNGO) Analyst Ratings
Bulls say
Bionano Genomics is set to see significant revenue growth in the coming years, driven by increased utilization of its optical genome mapping (OGM) technology across multiple industries including hematologic malignancies, constitutional genetics, and cell and gene therapy quality control. With a strong cash position and signs of expanding utilization in new regions, the company is well positioned to capitalize on its innovative technology. Risks include potential lower-than-projected market uptake and utilization, as well as potential need for additional capital. We reiterate a Buy rating and adjust our 12-month price target to $6 from $7 per share, using a conservative EV/Revenue of 1.5x for projected sales of $2.87 per share for FY2026.
Bears say
Bionano Genomics is showcasing its growing body of research and scaling high-volume solutions at the sold-out 2026 Bionano Symposium, highlighting OGM's ability to detect complex genomic rearrangements that traditional methods often miss. This is supported by published studies showing high concordance and superior detection of structural variants in various types of cancer, indicating potential for a broader application beyond liquid tumors. However, the company's financials show a cash runway only until 2Q26 and potential need for additional capital in the next 12 months. Despite the recent establishment of Category I CPT codes and multiple publications highlighting OGM's utility, the future growth and widespread adoption of OGM remains uncertain, leading to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.
Bionano Genomics (BNGO) Analyst Forecast & Price Prediction
Start investing in Bionano Genomics (BNGO)
Order type
Buy in
Order amount
Est. shares
0 shares